$283 Million is the total value of ACUTA CAPITAL PARTNERS, LLC's 47 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| New | AADI BIOSCIENCE | $44,919,000 | – | 1,529,402 | +100.0% | 15.85% | – | |
| BLU | New | BELLUS HEALTH | $12,326,000 | – | 2,007,500 | +100.0% | 4.35% | – |
| OLMA | New | OLEMA PHARMACEUTICALS | $4,148,000 | – | 150,500 | +100.0% | 1.46% | – |
| KRYS | New | KRYSTAL BIOTECH | $3,788,000 | – | 72,551 | +100.0% | 1.34% | – |
| CABA | New | CABALETTA BIO | $3,684,000 | – | 302,926 | +100.0% | 1.30% | – |
| GOSS | New | GOSSAMER BIO | $2,703,000 | – | 215,000 | +100.0% | 0.95% | – |
| MRUS | New | MERUS N V | $2,684,000 | – | 122,000 | +100.0% | 0.95% | – |
| AVDL | New | AVADEL PHARMACEUTICALS PLCcall | $2,450,000 | – | 250,000 | +100.0% | 0.86% | – |
| VRDN | New | VIRIDIAN THERAPEUTICS | $2,234,000 | – | 135,807 | +100.0% | 0.79% | – |
| ALLK | New | ALLAKOS | $1,853,000 | – | 17,500 | +100.0% | 0.65% | – |
| ALT | New | ALTIMMUNE | $1,697,000 | – | 150,000 | +100.0% | 0.60% | – |
| BCYC | New | BICYCLE THERAPEUTICS PLC SPONSORED ADSsponsored ads | $1,588,000 | – | 38,184 | +100.0% | 0.56% | – |
| New | ASTRIA THERAPEUTICS | $1,387,000 | – | 156,927 | +100.0% | 0.49% | – | |
| CCCC | New | C4 THERAPEUTICS STK | $938,000 | – | 21,000 | +100.0% | 0.33% | – |
| ELAN | New | ELANCO ANIMAL HEALTH | $925,000 | – | 29,000 | +100.0% | 0.33% | – |
| UTHR | New | UNITED THERAPEUTICS DEL | $554,000 | – | 3,000 | +100.0% | 0.20% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-11-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS INC | 24 | Q1 2023 | 21.2% |
| IRIDEX CORP | 20 | Q3 2019 | 8.1% |
| ARROWHEAD PHARMACEUTICALS INC | 20 | Q2 2023 | 7.9% |
| IMMUNOMEDICS INC | 19 | Q3 2020 | 20.6% |
| VERACYTE INC | 19 | Q3 2019 | 10.1% |
| ASCENDIS PHARMA A S | 18 | Q2 2020 | 7.2% |
| XENON PHARMACEUTICALS INC | 18 | Q3 2022 | 4.6% |
| CAS MED SYS PAR $0.004 | 18 | Q1 2019 | 6.4% |
| APELLIS PHARMACEUTICALS INC | 17 | Q3 2023 | 18.4% |
| KURA ONCOLOGY INC. COMMON STOCK | 17 | Q3 2023 | 8.1% |
View ACUTA CAPITAL PARTNERS, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| BCLS Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| Jiya Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| VistaGen Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
| CATALYST BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| Aadi Bioscience, Inc. | September 07, 2021 | 1,529,402 | 7.2% |
| Kadmon Holdings, Inc. | February 14, 2020 | 7,373,333 | 4.6% |
| IRIDEX CORPSold out | November 13, 2019 | 0 | 0.0% |
| ASSEMBLY BIOSCIENCES, INC. | February 14, 2019 | 718,500 | 2.8% |
| CAS MEDICAL SYSTEMS INC | February 14, 2019 | 5,263,508 | 18.2% |
View ACUTA CAPITAL PARTNERS, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View ACUTA CAPITAL PARTNERS, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.